MAB9012
抗-冠状病毒抗体，OC-43菌株，克隆541-8F
clone 541-8F, Chemicon®, from mouse
登录 查看组织和合同定价。
选择尺寸
关于此项目
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Clone:
541-8F, monoclonal
Species reactivity:
human
Application:
immunofluorescence
Technique(s):
immunofluorescence: suitable
Citations:
37
产品名称
抗-冠状病毒抗体，OC-43菌株，克隆541-8F, clone 541-8F, Chemicon®, from mouse
biological source
mouse
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
541-8F, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunofluorescence: suitable
shipped in
wet ice
Quality Level
Application
IFA。 最终工作稀释度必须由最终用户确定。
抗冠状病毒抗体，OC-43株，克隆541-8F可检测冠状病毒水平，&已发布&验证可用于IF。
研究子类别
传染病 - 病毒
传染病 - 病毒
研究类别
传染病
传染病
Biochem/physiol Actions
冠状病毒。
Disclaimer
除非我们的目录或产品随附的其他公司文件中另有说明，否则我们的产品预期仅用于研究用途，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或对人类或动物的任何类型的消费或应用。
Immunogen
表位：OC-43株
Physical form
形式：纯化
纯化的免疫球蛋白。提供在pH 7.4的PBS缓冲液中。含0.1%叠氮化钠和载体蛋白。
Preparation Note
自接收之日起，在2-8°C下保存长达6个月。
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Layla Pires et al.
Scientific reports, 12(1), 14438-14438 (2022-08-25)
The lack of therapeutic options to fight Covid-19 has contributed to the current global pandemic. Despite the emergence of effective vaccines, development of broad-spectrum antiviral treatment remains a significant challenge, in which antimicrobial photodynamic therapy (aPDT) may play a role
Kai-Wen Cheng et al.
Cells, 10(11) (2021-11-28)
Human coronavirus (HCoV) similar to other viruses rely on host cell machinery for both replication and to spread. The p97/VCP ATPase is associated with diverse pathways that may favor HCoV replication. In this study, we assessed the role of p97
Peifang Xie et al.
Phytomedicine : international journal of phytotherapy and phytopharmacology, 93, 153808-153808 (2021-11-10)
Qingwenjiere Mixture (QJM) is a traditional Chinese medicine (TCM) that has been shown to have remarkable clinical efficacy against COVID-19. However, little is known about the antiviral and anti-inflammatory activities of QJM against a wider range of human coronavirus (HCoV)
Yanmei Hu et al.
Journal of medical virology, 94(5), 2188-2200 (2022-01-27)
Brilacidin, a mimetic of host defense peptides (HDPs), is currently in Phase 2 clinical trial as an antibiotic drug candidate. A recent study reported that brilacidin has antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by inactivating the
Peifang Xie et al.
Frontiers in microbiology, 13, 845269-845269 (2022-06-28)
The human coronavirus OC43 (HCoV-OC43) is one of the most common causes of common cold but can lead to fatal pneumonia in children and elderly. However, the available animal models of HCoV-OC43 did not show respiratory symptoms that are insufficient
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持